KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Liabilities and Shareholders Equity: 2018-2025

Historic Liabilities and Shareholders Equity for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $364.0 million.

  • Esperion Therapeutics' Liabilities and Shareholders Equity rose 15.89% to $364.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 10.73%. This contributed to the annual value of $343.8 million for FY2024, which is 67.07% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Liabilities and Shareholders Equity of $364.0 million as of Q3 2025, which was up 4.88% from $347.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Liabilities and Shareholders Equity ranged from a high of $381.6 million in Q4 2021 and a low of $205.8 million during Q4 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $302.9 million, with a median of $324.0 million in 2025.
  • Per our database at Business Quant, Esperion Therapeutics' Liabilities and Shareholders Equity plummeted by 35.02% in 2022 and then spiked by 67.07% in 2024.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Liabilities and Shareholders Equity stood at $381.6 million in 2021, then crashed by 35.02% to $247.9 million in 2022, then fell by 17.00% to $205.8 million in 2023, then soared by 67.07% to $343.8 million in 2024, then climbed by 15.89% to $364.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $364.0 million in Q3 2025, compared to $347.1 million in Q2 2025 and $324.0 million in Q1 2025.